Overview: Phencyclidine Screen TestIntroduction: The Phencyclidine Screen Test screens for phencyclidine (PCP) to diagnose drug exposure, causing confusion or aggression. Aligned with 2023 SAMHSA guidelines, it uses toxicology methods for high specificity, supporting toxicology screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in toxicology for patients with suspected PCP exposure.
Other Names: PCP Screen Assay, Phencyclidine Drug Screen.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: PCP screening began in the 1970s with drug testing development. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Screens for PCP to diagnose drug exposure, guides treatment, and evaluates patients with confusion or aggression.
Test Parameters: 1. Phencyclidine Presence
Pretest Condition: No fasting required. Collect urine, serum, plasma, or hair. Report history of confusion, aggression, or drug exposure.
Specimen: Urine (sterile container, 5-20 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Hair (sterile container, 1-2 gm). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document confusion, aggression, or history of drug exposure. Include current medications, especially antipsychotics.
Consent: Written consent required, detailing the tests purpose, drug exposure implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to screen for PCP presence. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for drug exposure screening.
Factors Affecting Result Accuracy: Improper sample collection or contamination can affect results. Cross-reactivity with other drugs may reduce specificity.
Clinical Significance: Positive PCP screen suggests drug exposure, guiding confirmatory testing or treatment. Negative results may require GC-MS confirmation.
Specialist Consultation: Consult a toxicologist or addiction specialist for result interpretation and treatment planning.
Additional Supporting Tests: PCP confirmation test, urine drug panel, or clinical evaluation to confirm drug exposure.
Test Limitations: False positives may occur; clinical correlation is needed. Sample quality affects sensitivity.
References: SAMHSA Drug Testing Guidelines, 2023; Journal of Analytical Toxicology, Moeller KE, 2022.
